<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T06:05:46Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27361" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27361</identifier><datestamp>2026-09-24T20:52:13Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Gillgrass, Amy</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Lepard, Madeleine</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-02-07T16:25:12Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-02-07T16:25:12Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27361</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/20927</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Infection &amp; Immunity</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Currently, there are 38 million people living with human immunodeficiency virus (HIV-1) &#xd;
worldwide and there were 680,000 HIV-related deaths in 2020 alone. The greatest cause of &#xd;
mortality in people living with HIV (PLHIV) is infection with opportunistic pathogens such &#xd;
as tuberculosis (TB), which accounts for one third of HIV-related deaths. PLHIV are 20 &#xd;
times more susceptible to TB and co-infection leads to significantly worsened outcomes in &#xd;
terms of both diseases. Humanized mouse (hu-mouse) models, which possess human &#xd;
immune cells for HIV to infect, have been useful for HIV research. Our aim is to create hu- mouse models of HIV, TB and co-infection to investigate disease progression, immune &#xd;
responses, therapeutics, prevention and vaccination. NOD-Rag1null-IL2rgnull (NRG) mice are highly immunocompromised mice that are traditionally used to generate hu-mouse models. We are also developing NRG mice that are transgenic for human HLA-DR4 and HLA-A2 (DRAG-A2) and similar mice have been reported to have improved immune responses. NRG and DRAG-A2 mice were humanized with hematopoietic stem cells obtained from human umbilical cord blood. DRAG-A2 mice had significantly higher engraftment success rates (defined as the percentage of mice with >10% hCD45+) as well as higher overall CD45+ leukocyte, CD4+ T cell, CD19+ B cell and CD14+ monocyte reconstitution in the blood compared to huNRGs. huNRG mice were permissive to infection with JR-CSF or NL4.3-Bal-Env HIV-1 intravaginally or systemically. huDRAG-A2 mice were also infected intravaginally with NL4.3-Bal-Env HIV-1. huDRAG-A2 mice, but not huNRGs, produced HIV-specific IgG, indicating improved immune responses. huNRG mice were infected intranasally with mCherry-Erdman, YFP-H37Rv or H37Rv Mtb. huDRAG-A2 mice were also infected with H37Rv. Human immune cell involvement &#xd;
and human-like granuloma formation was observed using flow cytometry and immunohistopathology. These findings show that the DRAG-A2 model may be optimal for &#xd;
investigating HIV, TB and co-infection, which continue to be serious global health concerns.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Human immunodeficiency virus (HIV) and tuberculosis (TB) are infectious diseases that &#xd;
affect millions of people worldwide every year. The greatest cause of death in people living &#xd;
with HIV is co-infection with TB and HIV-positive individuals are much more likely to get &#xd;
TB. Humanized mouse (hu-mouse) models possess human immune cells for HIV to infect &#xd;
and are useful for studying HIV. Our goal is to create hu-mouse models of HIV, TB and &#xd;
HIV/TB co-infection that will allow us to study how these diseases interact. We are &#xd;
currently developing a traditional hu-mouse model (known as NRG), as well as an &#xd;
improved next-generation model (known as DRAG-A2) with a more functional immune &#xd;
system. Both models have been successfully infected with HIV or TB. Only DRAG-A2 &#xd;
mice were able to make antibodies against HIV. The improved DRAG-A2 model will&#xd;
enable future studies on HIV, TB and co-infection, which continue to be understudied &#xd;
global problems.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">HIV</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">TB</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Humanized mice</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Co-infection</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Developing and Utilizing a Next-Generation Humanized Mouse Model for Investigating HIV and Tuberculosis</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>